

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

1565

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/806639

INTERNATIONAL APPLICATION NO.

PCT/EP 99/07254

INTERNATIONAL FILING DATE

SEPTEMBER 30, 1999

PRIORITY DATE CLAIMED

OCTOBER 2, 1998

TITLE OF INVENTION

USE OF TESTOSTERONE ESTERS AND/OR TESTOSTERONE FOR PRODUCING BUCALLY APPLICABLE
BIO-ADHESIVE SYSTEMS WITH TIME-RELEASED ACTIVE INGREDIENTS

APPLICANT(S) FOR DO/EO/US

Dorie HUEBLER, Guenter KAUFMANN, Michael OETTEL, Holger ZIMMERMANN, Michael DITTGEN, Sabine
FRICKE, Manfred BOESE, Ralf LADWIG, Sven CLAUSSEN, Carsten TIMPE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☐ Other items or information:

EF 215953247 US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/7806639		INTERNATIONAL APPLICATION NO. PCT/EP 99/07254		ATTORNEY'S DOCKET NUMBER 1565	
---	--	---	--	---	--

20. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Search Report has been prepared by the EPO or JPO \$930.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) \$720.00 <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$790.00 <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,070.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$98.00				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1,000.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	6 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,000.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00	
SUBTOTAL =				\$1,000.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$1,000.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,000.00	
				Amount to be:	\$
				refunded	\$
				charged	\$

- ☐ A check in the amount of _____ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **19-4675** in the amount of **\$1,000.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **19-4675** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

STRIKER, STRIKER & STENBY
103 EAST NECK ROAD
HUNTINGTON, NEW YORK 11743

SIGNATURE

MICHAEL J. STRIKER

NAME

27233

REGISTRATION NUMBER

APRIL 2, 2001

DATE

09/806639

JC08 Rec'd PCT/PTO 02 APR 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Group: Attorney Docket # 1565

Applicant(s) : HUEBLER, D., ET AL

Serial No. :

Filed : Simultaneously

For : USE OF TESTOSTERONE ESTERS AND/OR
TESTOSTERONE FOR PRODUCING BUCALLY
APPLICABLE BIO-ADHESIVE SYSTEMS WITH TIME-
RELEASED ACTIVE INGREDIENTS

SIMULTANEOUS AMENDMENT

April 2, 2001

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

S I R S:

Simultaneously with filing of the above identified application
please amend the same as follows:

In the Claims:

Cancel all claims without prejudice.

Substitute the claims attached hereto.

REMARKS:

This Amendment is submitted simultaneously with filing of the above identified
application.

RECEIVED
APR 2 2001
UNITED STATES PATENT AND TRADEMARK OFFICE

[illegible]

Respectfully submitted,

~~Michael J. Striker~~
~~Attorney for Applicant(s)~~
~~Reg. No. 27233~~

Patentansprüche

- 5 1. Verwendung von Testosteronestern mit 1 bis 20 C-
Atomen im Carbonsäurerest oder Mischungen aus zwei
oder mehreren Testosteronestern mit unterschiedlichen
Carbonsäureresten und/oder Testosteron zur Herstel-
10 lung von bukkal applizierbaren bioadhäsiven Systemen
mit zeitlich gesteuerter Wirkstofffreisetzung zur Be-
handlung von Erkrankungen, welche mit einem veränder-
ten Testosteronspiegel einhergehen.
- 15 2. Verwendung gemäß Anspruch 1, dadurch gekennzeichnet,
daß die Kohlenstoffgerüste der Carbonsäurereste grad-
kettig, verzweigt, alicyclisch, gesättigt und/oder
ungesättigt mit bis zu fünf Doppel- und/oder Drei-
fachbindungen sind.
- 20 3. Verwendung gemäß Anspruch 1, dadurch gekenn-
zeichnet, daß das Verhältnis von Testosteron zu
Testosteronester 1 : 100 bis 1 : 1, vorzugsweise
25 1 : 10 bis 1 : 1,5 beträgt.
4. Verwendung gemäß Anspruch 1, dadurch
gekennzeichnet, daß die bukkal zu applizierenden
30 bioadhäsiven Systeme erhältlich sind, indem man die
Wirkstoffe zunächst getrennt oder gemeinsam in einem
Sprühtrocknungsverfahren amorph in organische Polyme-
re eingebettet.

5. Verwendung gemäß Anspruch 4, dadurch gekennzeichnet,
daß man die amorphen Testosteron-Sprühprodukte zusam-
men mit anderen Hilfsstoffen, Bindemitteln, Füllmit-
teln, Gleitmitteln, bioadhäsiven Polymeren, Tensiden,
5 Zerfallsbeschleunigern mischt und zu Ein- oder Mehr-
schichttabletten verpreßt.
6. Verwendung gemäß Anspruch 1
10 zur gezielten Einstellung therapeutischer^{und/} oder zirka-
dianer Rhythmen der Testosteronspiegel.

T0330 6E9080

**USE OF TESTOSTERONE ESTERS AND/OR TESTOSTERONE FOR
PRODUCING BUCCALLY APPLICABLE BIO-ADHESIVE SYSTEMS
WITH TIME-RELEASED ACTIVE INGREDIENTS**

The invention relates to a combination of testosterone and testosterone esters (or to the sole use of testosterone esters) in a buccal, bioadhesive preparation so that, by finely adjusted dosing of the active ingredients and ester selection, various desired plasma levels of testosterone can be set or produced in individual patients, for example to restore an endogenous circadian body rhythm.

Testosterone is quantitatively and qualitatively the most important androgen synthesized in the body. It is formed mainly in the testicles and in small amounts in the adrenal glands and in women in the ovaries. In males, testosterone is responsible for the development of the male characteristics during fetal, neonatal and pubertal maturation and finally for attaining the male phenotype and for androgen-dependent functions (for example spermatogenesis). Testosterone exerts protein-anabolic action (in muscles, bones, hematopoiesis, kidneys and liver) {E. Mutschler, "Arzneimittelwirkungen" [Drug Actions], 6th edition, pp. 334-337, Wissenschaftliche Verlagsgesellschaft mbh [publisher], Stuttgart, 1991}.

After oral or parenteral administration, testosterone is rapidly absorbed in the gastrointestinal tract. It is then transported by the portal vein to the liver where it is rapidly metabolized. As a result, the plasma half-life of testosterone is short, i.e., about 10 minutes {Auterhoff, H., Knabe, J. and Hölftje, H.D., "Lehrbuch der Pharmazeutischen Chemie" [Textbook of Pharmaceutical Chemistry], 12th edition, pp. 570-573, Wissenschaftliche Verlagsgesellschaft mbh [publisher], Stuttgart, 1991}. To develop a physiological serum level, oral administration of 400 mg (!) of testosterone is needed (S.G. Johnson, E.P. Bennet and V.G. Jensen, Therapeutic effectiveness of oral testosterone, Lancet 2:1974, 1473-1475).

To prolong the action of testosterone, testosterone esters with varying chain length (testosterone propionate, testosterone enantate, testosterone undecanoate) are injected intramuscularly as an oily solution or suspension. It is known that in contact with body fluids these esters will slowly hydrolyze under the action of esterases thus releasing the pharmacologically active testosterone. The influence of the type of ester on the growth of the capon comb after i.m. injection has already been described (Meier, R. and Tschopp, E., Arch. Exptl. Pathol. Pharmacol. 226:1955, 532).

Moreover, testosterone undecanoate (in oleic acid, as a soft gelatin capsule) is administered orally via the lymphatic route [Andriol® preparation]. From the oleic acid-embedded preparation, the drug passes from the gastrointestinal tract through the thoracic duct into the lymph tract thus reaching the systemic circulation. This gives rise to varying serum levels and gastrointestinal side effects. These effects can make long-term replacement therapy difficult (A.M. Matsumoto: Hormonal therapy of male hypogonadism, Endocrinol. Metab. Clin. North Am. 23:1994, 857-875).

04-8061639

Other routes of administration (transdermal, nasal, sublingual, buccal, subcutaneous) have been studied by various research groups (for example, by N.A. Mazer, W.E. Heiber, J.F. Moellmer, A.W. Meikle, J.D. Stringham, S.W. Sanders, K.G. Tolman and W.D. Odell, Enhanced transdermal delivery of testosterone: A new physiological approach for androgen replacement in hypogonadal men, J. Controll. Rel. 19:1992, 347-362).

Drawbacks of the aforesaid therapies are: 1. either a too short, rapidly decreasing testosterone level (after oral administration) or 2. - in the case of intramuscular injection of testosterone esters - the fact that a constantly set testosterone level cannot be changed over a long period of time (days to weeks) thus not allowing individual time control of the testosterone action. Moreover, down regulation of the basal testosterone secretion can take place.

The low bioavailability caused by the high first-pass effect in the liver can be circumvented by buccal or sublingual administration. Various studies confirm this (for example, Pitha, J., Anaissie, J. and Uekama, K., γ -Cyclodextrin: Testosterone complex suitable for sublingual administration, J. Pharmaceutical Sciences 76 (10):1987, 788-790).

Buccal administration of drugs is known from the prior art.

EP-0371466 A concerns a rapidly soluble tablet for fast buccal administration of steroids, among other things (for example estrogens, progestins). The main ingredient used is a water-soluble polyhydric alcohol, particularly sorbitol. The advantage is a rapid initial increase in drug concentration.

EP-0286581 A discloses the transmucosal buccal administration of estrogens (17β -estradiol and ethinylestradiol). The estrogen is used within the framework of hormone replacement therapy in postmenopausal women for treating PMS (postmenopausal syndrome) and for osteoporosis therapy at a dose of 50-100 μ g/day (17β -estradiol for PMS therapy) and at a dose of 200-400 μ g/day (17β -estradiol for osteoporosis therapy). Buccal administration makes it possible to attain therapeutic plasma levels by circumventing the first-pass effect.

WO-704342 describes a special formulation said to be particularly suitable for, among other things, the buccal administration of estrogens (for example estradiol and the esters of estradiol), progestins, androgens and anabolic steroids. This formulation contains a) about 1 - 20% of a soluble, adhesive polymer (carbomers, partly hydrolyzed polyvinyl alcohol [PVA], polyethylene oxide, polyacrylate, hydroxypropylmethylcellulose), b) a soluble, directly tabletted auxiliary agent and c) the active ingredient. The adhesive polymer makes the formulation or drug form adhere at the site of administration.

US-4396615-A describes the treatment of androgen-related diseases by administration of 6-methylene-progesterone, a testosterone-5 α -reductase inhibitor, in the form of topical formulations. Such formulations contain the inhibitor and an inert topical carrier (for example, a silicone, methylcellulose,

hydroxymethylcellulose).

CA-2105887-A discloses a bioerodable system for buccal and vaginal administration of hormones (estradiol), among other things. The system is water-soluble and mucoadherent. It consists of a solid, soluble, lyophilized foam and the active ingredient. The disintegration time is at least 8 hours. The system adheres to the mucosal membrane where it releases the drug. The polymers used are primarily gelatin, sodium carboxymethylcellulose, methylcellulose etc. A particular advantage of the system is its long adhesion time.

As regards the tailored time-release control of drugs, note that it is not possible for our currently available drugs to provide variable release of the active ingredient nor to adapt the release to the drug needs of an individual patient.

For release-control purposes, current depot drugs use passive dissolution, diffusion, swelling and erosion processes {Gröning, R., "Arzneiformen mit elektronisch gesteuerter Freisetzung" [Drug Forms with Electronically Controlled Release], in "Pharmazeutische Technologie: Moderne Arzneiformen" [Pharmaceutical Technology: Modern Drug Forms], p. 441, ed. [sic - Translator], Müller, R.H. and Hildebrand, G.E. (editors), Wissenschaftliche Verlagsgesellschaft mbh [publisher], Stuttgart, 1998}.

The time-controlled release of drugs is also known from the prior art.

JP-07118143 discloses time-controlled capsules which a) are water-insoluble or partly water-soluble, b) consist of water-swelling substances (powder, granulates or pills of, for example, calcium carboxymethylcellulose or polyvinylpyrrolidone) and c) contain elements (tablets) with the active ingredient in the center of the capsule.

The prior art also describes sustained-release preparations using polymers. Thus EP-068446, for example, discloses the use of methylcellulose or carboxymethylcellulose in sustained-release mixtures.

The object of the present invention is to make use of the advantages of buccal administration of steroids with high first-pass effect and low bioavailability, especially of testosterone and the esters thereof, by exploiting the different pharmacokinetics of the various testosterone esters (depending on chain length), so as to be able, by careful selection of appropriate dosages and esters, to attain a desired drug profile.

This objective is reached by use of testosterone esters with 1 to 20 carbon atoms in the carboxylic acid radical or of a mixture of two or more testosterone esters with different carboxylic acid radicals and/or testosterone, for the preparation of buccally administered bioadhesive systems with time-controlled release of the active ingredient, for treating diseases associated with a modified testosterone level.

Also preferred is a ratio of testosterone to testosterone ester from 1 : 100 to 1 : 1 and particularly from 1 : 10 to 1 : 1.5.

It is especially preferred to mix the amorphous, spray-dried testosterone products with other auxiliary agents, binders, fillers, lubricants, bioadhesive polymers, surfactants or disintegration accelerators and to compress the mixture into single-layer or multilayer tablets.

Surprisingly, we have now found that the chain length of the testosterone ester not only determines the solubility, but, as was shown experimentally, evidently also the kinetics of ester cleavage in the blood or tissue fluids by the corresponding hydrolases. Note in particular, when testosterone esters are employed, the use of the embedding technique of spray-drying in organic polymers (polyvinylpyrrolidone, hydroxypropylmethylcellulose, solid polyethylene glycols) to achieve improved solubility in the oral cavity. This is particularly important in view of the small saliva volumes (about 1 - 1.5 mL) which here, on the average, are available for the dissolution of sparingly soluble esters. In the publication by Jody Voorspoels [Vorspoels, J., Remon, J.P., Eechaute, W.E. and De Sy, W., Buccal Absorption of Testosterone and Its Esters Using a Bioadhesive Tablet in Dogs, *Pharmaceutical Research*, vol. 13, No. 8, 1996, 1228-1232], the testosterone esters (testosterone acetate, testosterone propionate, testosterone enantate, testosterone decanoate) studied in six castrated beagle dogs did not show a higher bioavailability than testosterone in spite of their higher lipophilicity. Because the esters were directly compressed only after dry mixing, without using a special premixing technology (amorphization by spray-drying), these poorer results presumably are due to the low, and in some cases extremely low, solubility of the esters in the crystalline state.

We were able to show that by the use of buccal administration of testosterone in combination with testosterone esters of different chain length, it is possible to attain different blood level patterns or rhythms (such as a circadian rhythm). In selecting the testosterone ester, the choice can be made specifically from three groups: 1. esters of shorter chain length (for example, testosterone acetate or propionate), 2. esters of medium chain length (for example testosterone enantate, cipionate or cyclohexanecarboxylate) and 3. esters of higher chain length (for example testosterone undecanoate, or

bucyclate).

According to the invention, this objective is reached by dissolving testosterone or the particular testosterone ester together with the polymer (for example polyvinylpyrrolidone or hydroxypropyl-methylcellulose) in ethanol and processing the mixtures further in a spray-drying unit to form an amorphous, embedded, spray-dried formulation. It is possible in this case 1) to embed said active ingredients separately from each other or 2) to embed them together in a single processing step, to obtain an amorphous mixture.

The fine-particle embedded spray-dried material is then subjected to dry mixing with other auxiliary agents for making bioadhesive buccal tablets [binders: polyvinylpyrrolidone, cellulose ethers; fillers: Cellactose®, mannitol, sorbitol, lactose; lubricants: magnesium stearate, hydrogenated vegetable fats; bioadhesive polymers: polyacrylates (Carbopols®, sodium carboxymethylcellulose) and optionally other auxiliary agents, such as surfactants or disintegration accelerators]. The mixture is then compressed into buccal tablets which can have a layered structure (active ingredient layer, bioadhesive layer; unidirectional or multidirectional release).

Based on blood level studies with the individual drug components alone, it is possible to attain the appropriate release patterns by changing the following two parameters

- dosage of the active ingredient
- selection of the ester or of the chain length at C-17.

An advantageous combination is, for example, that of the short-acting testosterone with testosterone undecanoate (eleven-carbon chain) which has a longer half-life (see practical examples).

To this end, an advantageous ratio of the active ingredients, namely of testosterone to Σ testosterone esters, is from 1 : 100 to 1 : 1 and particularly from 1 : 10 to 1 : 1.5.

By skillful combination of testosterone with testosterone esters, it is possible to attain blood level patterns which are capable of recreating or simulating the body's own rhythmicity of endogenous testosterone levels. For example, the duration of action of a bioadhesive buccal tablet with testosterone can be prolonged by combining testosterone with testosterone undecanoate (cf. Fig. 1 and Fig. 3). In the practical example (equimolar combination), the duration of blood levels of > 100 ng/mL is increased in female dogs from 2 to 4 hours. Moreover, a marked (slower) pulse is reached with a maximum appearing after about 3 hours. After 8 h, the testosterone values of nearly 50 ng/mL are still double as high as those attained with testosterone alone.

In essence, the set blood level pattern of testosterone is controlled through two parameters:

- * The chain length and steric structure of the ester chain at C-17. This structure determines, on the one hand, the lipophilicity and thus the solubility and, on the other, in a pronounced manner, the rate of ester cleavage and hydrolysis (interactions of the ester side chain with the active center of hydrolases). For example, esters with a longer chain length are cleaved more slowly than those with an intermediate or shorter chain length. In this sense, the released testosterone becomes available more slowly than after administration of pure testosterone, i.e. the peak appears later. Through the chain length, it is thus possible to attain a more or less tailored time control of therapeutic action.
- * The dosage of testosterone or of the testosterone esters on the basis of direct proportionality between the area under the curve [AUC] and the dose given.

This could be important for hormone replacement therapy in elderly men with partial androgen deficiency (PADAM patients) in that a deficient plasma level could be appropriately corrected.

The following practical examples illustrate the invention without limiting its scope.

EXAMPLE 1

Bioadhesive Tablet with Testosterone

Formulation

Component	Weight/tablet
Active ingredient layer	
Testosterone premix (20%)	50.00
Mannitol	43.90
Cellactose 80	29.50
Carmellose sodium	1.20
Magnesium stearate	1.50
Talc	4.50
Adhesive layer	
Mannitol	17.40
Cellactose 80	34.82
Carmellose sodium	10.18
Magnesium stearate	0.65
Red iron oxide	0.05
Talc	1.90

Preparation:

Preparation of the Premix

The testosterone premix (20%) was prepared by spray-drying. To this end, the active ingredient together with the polymer (for example, polyvinylpyrrolidone, hydroxypropylmethylcellulose) and optionally another auxiliary agent (carrier or antistatic agent) were dissolved or suspended in an appropriate solvent. The homogenized suspension obtained by steady stirring was spray-dried in a spray-drying unit to obtain a fine powder.

Preparation of the Active Ingredient Layer

This premix was mixed with the other auxiliary agents for the active ingredient layer (mannitol, Cellactose 80) in an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc) for about 20 minutes. The outer phase (Carmellose sodium, magnesium stearate, talc) was then added, and mixing was continued for 5 minutes.

Preparation of the Adhesive Layer

Red iron oxide and talc were intimately ground in a ball mill. In an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc), mannitol and Cellalactose 80 were mixed for about 20 min. The ground colored mixture, Carmellose sodium and magnesium stearate were then added as the outer phase, and mixing was continued for an additional 5 minutes.

The mixtures for the active ingredient layer and adhesive layer, in the weight ratio given, were then compressed in an appropriate tableting press to form two-layer tablets.

Fig. 1 shows the blood level variation for a formulation according to Example 1.

EXAMPLE 2**Bioadhesive Tablet with Testosterone Undecanoate****Formulation**

Component	Weight/tablet
Active ingredient layer	
Testosterone undecanoate premix (20%)	50.00
Mannitol	43.90
Cellactose 80	29.50
Carmellose sodium	1.20
Magnesium stearate	1.50
Talc	4.30
Adhesive layer	
Mannitol	17.40
Cellactose 80	34.82
Carmellose sodium	10.18
Magnesium stearate	0.65
Red iron oxide	0.05
Talc	1.90

Preparation:**Preparation of the Premix**

The testosterone undecanoate premix (20%) was prepared by spray-drying. To this end, the active ingredient together with the polymer (for example, polyvinylpyrrolidone, hydroxypropylmethylcellulose) and optionally another auxiliary agent (carrier or antistatic agent) were dissolved or suspended in an appropriate solvent. The homogenized suspension obtained by steady stirring was spray-dried in a spray-drying unit to obtain a fine powder.

Preparation of the Active Ingredient Layer

This premix was mixed with other auxiliary agents for the active ingredient layer (mannitol, Cellactose 80) in an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc) for about 20 minutes. The outer phase (Carmellose sodium, magnesium stearate, talc) was then added, and mixing was

continued for 5 minutes.

Preparation of the Adhesive Layer

Red iron oxide and talc were intimately ground in a ball mill. In an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc), mannitol and Cellalactose 80 were mixed for about 20 min. The ground colored mixture, Carmellose sodium and magnesium stearate were then added as the outer phase, and mixing was continued for an additional 5 minutes.

The mixtures for the active ingredient layer and adhesive layer, in the weight ratio given, were then compressed in an appropriate tableting press to obtain two-layer tablets.

Fig. 2 shows the blood level variation for a formulation according to Example 2

EXAMPLE 3

Bioadhesive Tablet with Testosterone and Testosterone Undecanoate

Formulation

Component	Weight/tablet
Active ingredient layer	
Testosterone/ testosterone undecanoate premix (20%, 20%)	50.00
Mannitol	43.90
Cellactose 80	29.50
Carmellose sodium	1.20
Magnesium stearate	1.50
Talc	4.30
Adhesive layer	
Mannitol	17.40
Cellactose 80	34.82
Carmellose sodium	10.18
Magnesium stearate	0.65
Red iron oxide	0.05
Talc	1.90

Downloaded by [REDACTED]

The testosterone/testosterone undecanoate premix (20%) was prepared by spray-drying. To this end, the active ingredient together with the polymer (for example, polyvinylpyrrolidone, hydroxypropylmethylcellulose) and optionally another auxiliary agent (carrier or antistatic agent) were dissolved or suspended in an appropriate solvent. The homogenized suspension obtained by steady stirring was spray-dried in a spray-drying unit to obtain a fine powder.

This premix was mixed with other auxiliary agents for the active ingredient layer (mannitol, Cellactose 80) in an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc) for about 20 minutes. The outer phase (Carmellose sodium, magnesium stearate, talc) was then added, and mixing was continued for 5 minutes.

Red iron oxide and talc were intimately ground in a ball mill. In an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc), mannitol and Cellalactose 80 were mixed for about 20 min. The ground colored mixture, Carmellose sodium and magnesium stearate were then added as the outer phase, and mixing was continued for an additional 5 minutes.

Fig. 3 shows the blood level variation for a formulation according to Example 3.

EXAMPLE 4**Bioadhesive Tablet with Testosterone and Testosterone Enantate****Formulation**

Component	Weight/tablet
Active ingredient layer	
Testosterone/ testosterone enantate premix (20%, 20%)	50.00
Mannitol	58.60
Emcompress	14.00
Carbopol® 974	2.00
Magnesium stearate	1.50
Talc	4.30
Adhesive layer	
Mannitol	17.40
Emcompress	34.82
Carbopol® 974	13.00
Magnesium stearate	0.65
Red iron oxide	0.05
Talc	1.90

Preparation:**Preparation of the Premix**

The testosterone/testosterone enantate premix (20%) was prepared by spray-drying. To this end, the active ingredient together with the polymer (for example, polyvinylpyrrolidone, hydroxypropylmethyl-cellulose and optionally another auxiliary agent (carrier or antistatic agent) were dissolved or suspended in an appropriate solvent. The homogenized suspension obtained by steady stirring was spray-dried in a spray-drying unit to form a fine powder.

Preparation of the Active Ingredient Layer

This premix was mixed with other auxiliary agents for the active ingredient layer (mannitol, Emcompress) in an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc) for about 20 minutes. The outer phase (Carbopol® 974, magnesium stearate, talc) was then added, and mixing

was continued for 5 minutes.

Preparation of the Adhesive Layer

Red iron oxide and talc were intimately ground in a ball mill. In an appropriate mixer (type: Kubu mixer, Turbula mixer, tumble mixer etc), mannitol and Emcompress were mixed for about 20 min. The ground colored mixture, Carbopol® 974 and magnesium stearate were then added as the outer phase, and mixing was continued for an additional 5 minutes.

The mixtures for the active ingredient layer and adhesive layer, in the weight ratio given, were then compressed in an appropriate tableting press to form two-layer tablets.

EXAMPLE 5

Bioadhesive Tablet with Testosterone Propionate and Testosterone Undecanoate

Formulation

Component	Weight/tablet
Active ingredient layer	
Testosterone propionate/ testosterone enantate premix (20%, 20%)	50.00
Mannitol	58.60
Emcompress	14.00
Carbopol® 974	2.00
Magnesium stearate	1.50
Talc	4.30
Adhesive layer	
Mannitol	17.40
Emcompress	34.82
Carbopol® 974	13.00
Magnesium stearate	0.65
Red iron oxide	0.05
Talc	1.90

Preparation of the Premix

Preparation of the Active Ingredient Layer

Preparation of the Adhesive Layer

The mixtures for the active ingredient layer and adhesive layer, in the weight ratio given, were then compressed in an appropriate tableting press to form two-layer tablets.

PATENT CLAIMS

1. Use of testosterone esters with 1 to 20 carbon atoms in the carboxylic acid radical or of mixtures of two or more testosterone esters with different carboxylic acid radicals and/or of testosterone for preparing buccally administered bioadhesive systems with time-controlled active ingredient release, for treating diseases associated with a modified testosterone level.
2. Use according to Claim 1, characterized in that the carbon structures of the carboxylic acid radicals are linear, branched, alicyclic, saturated and/or unsaturated and have up to five double and/or triple bonds.
3. Use according to Claim 1 or 2, characterized in that the ratio of testosterone to testosterone ester is from 1 : 100 to 1 : 1 and preferably from 1 : 10 to 1 : 1.5.
4. Use according to one of Claims 1 to 3, characterized in that the buccally administered bioadhesive systems are obtained by first embedding the amorphous active ingredients as obtained by a spray-drying process, separately or conjointly, into an organic polymer.
5. Use according to Claim 4, characterized in that the amorphous spray-dried testosterone products are mixed with other auxiliary agents, binders, fillers, lubricants, bioadhesive polymers, surfactants or disintegration accelerators, and the mixture is then compressed to form single-layer or multilayer tablets.
6. Use according to one of the preceding claims for the purpose of attaining in a tailored manner a therapeutic and/or circadian rhythm of the testosterone level.

ABSTRACT

The use of testosterone esters with 1 to 20 carbon atoms in the carboxylic acid radical or of mixtures of two or more testosterone esters with different carboxylic acid radicals and/or of testosterone, for producing buccally administered bioadhesive systems with time-controlled release of the active ingredient for the treatment of diseases associated with a modified testosterone level.

The use according to the invention makes it possible to attain in a tailored manner a therapeutic and/or circadian rhythm of the testosterone level.

Fig. 1




Fig. 2





Fig. 3



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Group:

Attorney Docket # 1565

Applicant(s): HUEBLER, D., ET AL

Serial No.: 09/806,639

Filed: 04/02/2001

For : USE OF TESTOSTERONE ESTERS AND/OR
TESTOSTERONE FOR PRODUCING BUCALLY
APPLICABLE BIO-ADHESIVE SYSTEMS WITH
TIME-RELEASED ACTIVE INGREDIENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

May 16, 2001

Sir:

The subject application was filed without the signature of the inventors and in the German language.

Declaration papers executed by the inventors and a Certified English Translation of the application are submitted herewith.

It is respectfully requested that the required fee be charged to the account of the undersigned (19-4675).

Respectfully submitted,

Box: PCT
Michael J. Striker
Attorney for Applicant(s)
Reg. No. 27233

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

On 5/17/01
6772

SEARCHED	INDEXED
SERIALIZED	FILED
MAY 16 2001	
FBI - NEW YORK	
19-4675	
152-120	

60/106,520	NOVEMBER 3, 1998
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)
(Application Serial No.)	(Filing Date)

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

Form PTO-SB-01 (6-95) (Modified)

Docket No.
1565

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

USE OF TESTOSTERONE ESTERS AND/OR TESTOSTERONE FOR PRODUCING BUCALLY APPLICABLE BIO-ADHESIVE SYSTEMS WITH TIME-RELEASED ACTIVE INGREDIENTS

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on SEPTEMBER 30, 1999 as United States Application No. or PCT International Application Number PCT/EP 99/07254 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
<u>198 47 252.8</u>	<u>GERMANY</u>	<u>October 2, 1998</u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

MICHAEL J. STRIKER

REG. NO.: 27233

Send Correspondence to: **MICHAEL J. STRIKER**
103 EAST NECK ROAD
HUNTINGTON, NY 11743

Direct Telephone Calls to: *(name and telephone number)*
MICHAEL J. STRIKER, TEL. (631) 549 4700

Full name of sole or first inventor

Doris HUEBLER

Sole or first inventor's signature

Doris Huebler

Date

April 27th, 2001

Residence

NR. 12, D-07407 SCHMIEDEN, GERMANY

DEV

Citizenship

GERMAN

Post Office Address

NR. 12, D-07407 SCHMIEDEN, GERMANY

Full name of second inventor, if any

Guenter KAUFMANN

Second inventor's signature

Guenter Kaufmann

Date

May 2nd, 2001

Residence

SCHILLBACHSTRASSE 41, D-07743 JENA, GERMANY

DEV

Citizenship

GERMAN

Post Office Address

SCHILLBACHSTRASSE 41, D-07743 JENA, GERMANY

300

Full name of third inventor, if any Michael OETTEL	
Third inventor's signature <i>Michael Oettel</i>	Date April 26th, 2001
Residence BEETHOVENSTRASSE 30, D-07743 JENA, GERMANY	
Citizenship GERMAN	DEY
Post Office Address BEETHOVENSTRASSE 30, D-07743 JENA, GERMANY	

400

Full name of fourth inventor, if any Holger ZIMMERMANN	
Fourth inventor's signature <i>Holger Zimmermann</i>	Date May 2nd, 2001
Residence TRINIUSSTRASSE 12, D-98693 ILMENAU-RODA, GERMANY	
Citizenship GERMAN	DEY
Post Office Address TRINIUSSTRASSE 12, D-98693 ILMENAU-RODA, GERMANY	

500

Full name of fifth inventor, if any Michael DITTGEN	
Fifth inventor's signature <i>Michael Dittgen</i>	Date May 3rd, 2001
Residence HEIDENBERG 35/37, D-99510 APOLDA, GERMANY	
Citizenship GERMAN	DEY
Post Office Address HEIDENBERG 35/37, D-99510 APOLDA, GERMANY	

600

Full name of sixth inventor, if any Sabine FRICKE	
Sixth inventor's signature <i>Sabine Fricke</i>	Date May 7th, 2001
Residence AN DER RIESE 1B, D-07749 JENA, GERMANY	DEY
Citizenship GERMAN	
Post Office Address AN DER RIESE 1B, D-07749 JENA, GERMANY	

700

Full name of seventh inventor, if any Manfred BOESE	
Seventh inventor's signature <i>[Signature]</i>	Date May 6 th , 2001
Residence MAGDELSTIEG 106, D-07745 JENA, GERMANY	geändert in: LUTHERSTRASSE 2, D-07743 JENA, GERMANY
Citizenship GERMAN	DEU
Post Office Address MAGDELSTIEG 106, D-07745 JENA, GERMANY	geändert in: LUTHERSTRASSE 2, D-07743 JENA, GERMANY

800

Full name of eighth inventor, if any Ralf LADWIG	
Eighth inventor's signature <i>[Signature]</i>	Date May 4 th , 2001
Residence HANNS-EISLER-STRASSE 16, D-07745 JENA, GERMANY	geändert in: IM BÜRGERGARTEN 33, D-07747 JENA, GERMANY
Citizenship GERMAN	DEU
Post Office Address HANNS-EISLER-STRASSE 16, D-07745 JENA, GERMANY	geändert in: IM BÜRGERGARTEN 33, D-07747 JENA, GERMANY

900

Full name of ninth inventor, if any Sven CLAUSSEN	
Ninth inventor's signature <i>[Signature]</i>	Date May 4 th , 2001
Residence DORNBURGER STRASSE 99, D-07743 JENA, GERMANY	geändert in: KRONFELDSTRASSE 6, D-07745 JENA, GERMANY
Citizenship GERMAN	DEU
Post Office Address DORNBURGER STRASSE 99, D-07743 JENA, GERMANY	geändert in: KRONFELDSTRASSE 6, D-07745 JENA, GERMANY

Full name of tenth inventor, if any Carsten TIMPE	
Tenth inventor's signature	Date
Residence AUF DEM PRITZEL 18, D-37299 WEISSENBORN, GERMANY	
Citizenship GERMAN	
Post Office Address AUF DEM PRITZEL 18, D-37299 WEISSENBORN, GERMANY	

Full name of seventh inventor, if any Manfred BOESE	
Seventh inventor's signature	Date
Residence MAGDELSTIEG 106, D-07745 JENA, GERMANY	
Citizenship GERMAN	
Post Office Address MAGDELSTIEG 106, D-07745 JENA, GERMANY	

Full name of eighth inventor, if any Ralf LADWIG	
Eighth inventor's signature	Date
Residence HANNS-EISLER-STRASSE 16, D-07745 JENA, GERMANY	
Citizenship GERMAN	
Post Office Address HANNS-EISLER-STRASSE 16, D-07745 JENA, GERMANY	

Full name of ninth inventor, if any Sven CLAUSSEN	
Ninth inventor's signature	Date
Residence DORNBURGER STRASSE 99, D-07743 JENA, GERMANY	
Citizenship GERMAN	
Post Office Address DORNBURGER STRASSE 99, D-07743 JENA, GERMANY	

Full name of tenth inventor, if any Carsten TIMPE	
Tenth inventor's signature	Date 30.04.01
Residence AUF DEM PRITZEL 18, D-37299 WEISSENBORN, GERMANY	geändert in: ALTER POSTWEG 43a, D-24558 HENSTEDT/ULZBURG, GERMANY
Citizenship GERMAN	DEX
Post Office Address AUF DEM PRITZEL 18, D-37299 WEISSENBORN, GERMANY	geändert in: ALTER POSTWEG 43a, D-24558 HENSTEDT/ULZBURG, GERMANY